ArticleMediators of inflammation2026
Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF-β1/Smad Signaling Pathway.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF-β1/Smad Signaling Pathway.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aimed to clarify the pharmacodynamic effects of YaJieShaBa (YJSB) against alcoholic hepatic fibrosis (HF) and elucidate its mechanism in regulating the transforming growth factor-β1 (TGF-β1)/Smad pathway.
methodsInduce the alcoholic HF model in rats using 56% ethanol (10 mL/kg). The pharmacological efficacy of YJSB in combating liver fibrosis was evaluated through comprehensive assessments of key indicators: body weight, liver mass and index, biochemical liver function parameters (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), liver fibrosis biomarkers (type Ⅲ procollagen amino-terminal propeptide [PⅢNP], type-Ⅳ collagen (COL-Ⅳ), laminin (LN), and hyaluronic acid [HA]), serum hydroxyproline (Hyp) and TGF-β1 levels, hepatocyte homogenate levels of COL-I, COL-Ⅲ, and α-smooth muscle actin (α-SMA), along with histopathological changes observed in liver tissue via hematoxylin and eosin (H&E) staining, Ag staining, and Masson staining. Pathway-focused qPCR array analysis was used to detect the expression of 72 genes related to signaling pathways such as TGF-β1, Keap1-Nrf2, and TLR4/MyD88 in liver tissue from the control group, model group, and YJSB group, identifying differentially expressed genes (DEGs) and key signaling pathways between the model group and the YJSB treatment group. Finally, based on the results of the pathway-focused qPCR array, the mechanism of action of YJSB against HF was validated using ELISA, WB, and immunofluorescence methods. Concurrently, TGF-β1 receptor inhibitors were employed in vitro experiments to determine whether YJSB could still provide additional protective effects when the TGF-β1/Smad pathway was maximally blocked. Furthermore, after confirming that YJSB could inhibit TGF-β1-induced activation, a rescue experiment was conducted by adding exogenous TGF-β1 to observe whether it could reverse the inhibitory effects of YJSB.
resultsYJSB administration significantly increased body mass and decreased liver index in alcoholic HF rats. Serum levels of AST, ALT, PⅢNP, COL-Ⅳ, LN, HA, Hyp, and TGF-β1 were significantly reduced, as were the levels of COL-I, Ⅲ, and α-SMA in liver homogenates. Histological analyses, including H&E, Ag, and Masson staining, revealed a significant reduction in liver damage. Pathway-focused qPCR array results showed that, compared with the blank group, 65 genes were upregulated and seven genes were downregulated in the model group, among which the relative expression levels of 40 genes were statistically significant (expression change factor ≥ 1 and p < 0.05). Compared with the model group, 68 genes were downregulated, and four genes were upregulated in the YJSB group, with 34 genes showing statistically significant relative expression levels (fold change [FC] ≥ 2 and p < 0.05). The DEGs were primarily enriched in the TGF-β1 signaling pathway. Additionally, YJSB reduced the levels of inflammatory factors IL-1β, TNF-α, IL-6, and IL-8 in liver tissue homogenates while increasing SOD, GSH-Px, and catalase (CAT) levels and decreasing MDA and ROS levels. Western blotting results showed that YJSB downregulated the expression levels of TGF-β1, Smad2, Smad3, P-Smad2, and P-Smad3 in the liver. Immunofluorescence results indicated that YJSB downregulated the expression levels of Smad4 in hepatocyte nuclei. In vitro experiments demonstrated that the mechanism of YJSB involves primarily inhibiting TGF-βR1 receptor activation, effectively downregulating P-Smad2/3 protein levels, as validated by the TGF-βR1 inhibitor LY2157299. Concurrently, in rescue experiments, the inhibitory effect of YJSB on P-Smad2/3 protein was partially reversed by exogenous TGF-β1, indicating that YJSB's antifibrotic action is highly correlated with the TGF-β1/Smad pathway.
conclusionYJSB effectively inhibits the inflammatory and oxidative stress-related cascade by regulating the TGF-β1/Smad signaling pathway (TSSP), thus suppressing the progression of alcoholic HF. This demonstrates that YJSB possesses potential for combating alcoholic HF in animal models, providing experimental evidence for its subsequent research and clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.